Multiple sclerosis (MS) is one of the most common autoimmune diseases affecting the brain and spinal cord, with 2.9 million ...

A groundbreaking new trial is set to investigate whether an mRNA jab, designed to target the Epstein-Barr virus (EBV), could ...

About 1 million people in the U.S. live with multiple sclerosis, a chronic autoimmune disease that inflames the nervous ...

A team from UNIGE and HUG has discovered a subgroup of immune cells particularly involved in the disease, opening the way to ...

The damage can lead to both sudden “flares” of inflammation and a slow worsening of symptoms over time. Historically, MS has been broken down into specific subtypes, as detailed below. But the reality ...

Scientists are trying a revolutionary new approach to treat rheumatoid arthritis, multiple sclerosis, lupus and ...

TG Therapeutics remains attractive for investors despite competition and slowing growth. Read the latest analysis on the ...

Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States ...

Multiple Sclerosis (MS) affects women far more often than men, with the current sex ratio sitting at approximately 3:1. We ...

A multiple sclerosis diagnosis used to mean a future of disability. But now, a revolution in medications allows MS patients to pursue their dreams.

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a rare autoimmune condition in which the body's ...

Advances being used to treat cancer are now being applied to lupus, rheumatoid arthritis, and other disorders.